Understanding cardiac tumors and their risks
Official title: Characteristics of Cardiac Tumor and the Risk Stratification of Subsequent Adverse Events (UNIQUE): an Investigator-initiated, National, Multicenter, Retrospective-prospective, Cohort Study
Run by First Affiliated Hospital Xi'an Jiaotong University · NCT06100328 · Data updated 2026-11-12
This study is trying to gather information from patients with heart tumors to better understand their risks and develop a way to predict how these tumors might behave over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 3 Years to 80 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Status | Recruiting |
| Started | October 26, 2023 |
| Main results expected | July 31, 2030 |
| Study ends | July 31, 2030 |
| Registry record updated | July 12, 2024 |
| Trial ID | NCT06100328 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with various types of cardiac tumors who are regularly followed up at a cardiovascular center.
✕Probably not a fit
Patients under 3 years or over 80 years old, pregnant or lactating women, and those unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to collect and analyze clinical and biological data from patients diagnosed with cardiac tumors, both retrospectively and prospectively. It will utilize various techniques, including molecular biology and multi-omics analysis, to develop a prognostic model for these tumors. The research will involve a long-term follow-up cohort and management system, assessing disease characteristics, progression patterns, and long-term prognosis. Data will be gathered from cases spanning from 2003 to 2030, creating a comprehensive understanding of cardiac tumors.
Why it matters
Potential benefit: If successful, this study could improve risk stratification and management of patients with cardiac tumors.
How similar studies have gone: While there have been studies on cardiac tumors, this approach of combining retrospective and prospective data collection with multi-omics analysis is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are regularly visited and followed up in the corresponding cardiovascular center. * All patients must meet at least one of the following diagnostic criteria for cardiac neoplasms: 1. Cardiac myxoma group; 2. Cardiac fibroma group; 3. Cardiac lipoma group; 4. Cardiac hemangioma group; 5. Cardiac undifferentiated sarcoma; 6. Cardiac angiosarcoma group; 7. Cardiac rhabdomyosarcoma group; 8. Cardiac lymphoma group; 9. Cardiac metastasis group; 10. Other cardiac tumors group. Exclusion Criteria: * Age \<3 years or \>80 years old. * Pregnant and lactating women. * The patient declined to provide informed consent to participate in the study. * None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.
Where it's running
-
First Affiliated Hospital of Xi'an Jiantong University
Xi'an, Shaanxi, China Recruiting
Study contacts
- Principal investigator: Guoliang Li — First Affiliated Hospital Xi'an Jiaotong University
- Study coordinator: Guoliang Li
- Email: liguoliang_med@163.com
- Phone: +8613759982523
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating the safety of endocardial myocardial biopsy procedures
This study is testing the safety of a heart tissue biopsy procedure for patients with heart issues like myocarditis and cardiomyopathies to see how well it works and what risks it might have.
-
Neoadjuvant therapy with adebrelimab, famitinib, and chemotherapy for resectable ESCC
This study tests a combination of adebrelimab, famitinib, and chemotherapy before surgery in people with resectable locally advanced esophageal squamous cell carcinoma to see if it can lead to a complete tumor disappearance at the time of surgery.
-
Blood lipid and ceramide profiles in atrial fibrillation
This study tests whether blood lipid and ceramide patterns differ between people with atrial fibrillation and those with other heart diseases.
-
Early use of oral Realgar-Indigo Naturalis plus all-trans retinoic acid for acute promyelocytic leukemia
This study will test whether starting an oral arsenic medicine called Realgar-Indigo Naturalis Formula (RIF) together with all-trans retinoic acid (ATRA) early in treatment can lower early deaths in adults with acute promyelocytic leukemia (APL).
-
rhPro-UK before endovascular stroke treatment in the extended window
In adults with acute ischemic stroke due to a large vessel blockage, this trial tests whether giving rhPro-UK before thrombectomy in the 4.5–24 hour window helps people recover better than a placebo.
-
Letermovir versus valganciclovir to prevent CMV in kidney transplant recipients
This trial tests whether letermovir works as well as valganciclovir to prevent CMV infection and disease in adults within a week after a kidney transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.